Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE

MLA

Ilan, Ezgi, et al. Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE. 2015. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1235012103&authtype=sso&custid=ns315887.

APA

Ilan, E., Sandström, M., Wassberg, C., Sundin, A., Garske-Román, U., Eriksson, B., Granberg, D., & Lubberink, M. (2015). Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE.

Chicago

Ilan, Ezgi, Mattias Sandström, Cecilia Wassberg, Anders Sundin, Ulrike Garske-Román, Barbro Eriksson, Dan Granberg, and Mark Lubberink. 2015. “Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1235012103&authtype=sso&custid=ns315887.